Indian Pharmacopoeia Commission hosts scientific conclave to brainstorm on strengthening pharmaceutical quality and compliance
FY26 revenue rises to Rs. 4,359 crore as India’s leading CDMO strengthens global footprint with EU GMP certifications, UK MHRA approval and Europe supplies
The product is manufactured at AKUMS’ state-of-the-art injectable facility in Kotdwar, Uttarakhand
Operational leverage kicked in during the quarter, with adjusted EBITDA rising 21% year-on-year to Rs 147 crore
Plant 1 continues to serve as a core manufacturing hub for oral solid dosage forms
It will produce a comprehensive range of dosage forms including tablets, hard gelatin capsules, liquids, injectables, topicals, and beta-lactam products
During this quarter, the company achieved a key milestone of reaching 1,000 DCGI approvals
Akums invested Rs. 272 crore in capital expenditure during FY25
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
